Corcept Therapeutics Incorporat CORT
Price alert —
Sign in to get a one-time email the moment CORT crosses your price. Free accounts included.
Sign in / create a free accountPrice chart
Loading…
Latest bar · CORT
Momentum reads · latest daily barGreen means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.
Financial overlay · last 12 quarters
The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.
| Quarter | Revenue | Net income | Op income | FCF | Net margin | Op margin |
|---|---|---|---|---|---|---|
| 2026-03-31 | $0.2B | $-0.0B | $-0.0B | $-0.0B | -19.3% | -30.1% |
| 2025-12-31 | $0.2B | $0.0B | $0.0B | $0.0B | 12.0% | 2.2% |
| 2025-09-30 | $0.2B | $0.0B | $0.0B | $0.1B | 9.5% | 4.9% |
| 2025-06-30 | $0.2B | $0.0B | $0.0B | $0.0B | 18.1% | 13.7% |
| 2025-03-31 | $0.2B | $0.0B | $0.0B | $0.0B | 13.1% | 2.2% |
| 2024-12-31 | $nanB | $nanB | $nanB | $nanB | nan% | nan% |
Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.
Compare CORT vs peers
Line CORT up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.
Add tickers to compare with CORT
~30 metrics across Snapshot, OdysseyHQ zone, Valuation, Growth, Quality, Technicals, Sentiment, and Risk — with a weighted score and a one-line read on each.
Earnings replay · last 20 reports
How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.
| Date | EPS actual | EPS est | Surprise | Next-day |
|---|---|---|---|---|
| 2026-04-30 | -0.30 | -0.14 | -111.3% | +10.5% |
| 2026-02-24 | 0.20 | 0.33 | -39.4% | -0.7% |
| 2025-11-04 | 0.16 | 0.14 | +18.5% | +7.8% |
| 2025-07-31 | 0.29 | 0.19 | +54.7% | +2.7% |
| 2025-05-05 | 0.17 | 0.14 | +19.3% | -4.3% |
| 2025-02-26 | 0.26 | 0.42 | -38.6% | -5.5% |
| 2024-10-30 | 0.41 | 0.29 | +41.4% | +4.4% |
| 2024-07-29 | 0.32 | 0.24 | +34.7% | -1.1% |
| 2024-05-01 | 0.25 | 0.22 | +13.6% | +4.9% |
| 2024-02-15 | 0.28 | 0.27 | +3.7% | -7.2% |
| 2023-11-01 | 0.28 | 0.23 | +21.7% | -10.0% |
| 2023-08-02 | 0.25 | 0.15 | +64.5% | +24.9% |
| 2023-05-03 | 0.14 | 0.21 | -32.7% | +3.9% |
| 2023-02-28 | 0.14 | 0.28 | -49.4% | -4.7% |
| 2022-11-03 | 0.30 | 0.28 | +7.1% | -10.4% |
| 2022-08-03 | 0.24 | 0.28 | -15.3% | -1.3% |
| 2022-05-05 | 0.20 | 0.31 | -35.5% | -9.9% |
| 2022-02-15 | 0.35 | 0.35 | — | +12.8% |
| 2021-11-03 | 0.24 | 0.21 | +14.3% | +10.1% |
| 2021-07-29 | 0.30 | 0.17 | +81.8% | +2.4% |
Earnings markers are overlaid on the daily price chart above. Click a ▲ marker for that day's move.
Peer comparison · Healthcare
Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.
| Ticker ⇅ | Mkt cap ⇅ | P/E ⇅ | Fwd P/E ⇅ | P/S ⇅ | EV/EBITDA ⇅ | P/B ⇅ | Gross M ⇅ | Rev gr ⇅ | EPS gr ⇅ | FCF yld ⇅ |
|---|---|---|---|---|---|---|---|---|---|---|
| CORT ★ | $10B | 254.4 | 28.6 | 12.8 | -1370.1 | 15.4 | 98.2% | 4.9% | — | 1.18% |
| LLY | $1,023B | 41.8 | 25.5 | 14.2 | 29.3 | 32.8 | 82.8% | 55.5% | 169.9% | 0.90% |
| UNH | $383B | 32.1 | 18.8 | 0.9 | 17.5 | 3.9 | 19.5% | 0.4% | 61.5% | 5.95% |
| JNJ | $599B | 29.3 | 19.4 | 6.1 | 18.1 | 7.4 | 68.1% | 6.6% | -1.0% | — |
| MRK | $307B | 36.0 | 12.9 | 4.7 | 11.9 | 6.7 | 76.7% | 4.9% | — | 4.57% |
| ABBV | $448B | 124.8 | 15.6 | 7.1 | 17.1 | -67.3 | 72.0% | 12.4% | -46.2% | 4.65% |
| PFE | $141B | 19.2 | 8.7 | 2.2 | 7.6 | 1.6 | 74.8% | 5.4% | -10.1% | 8.77% |
| TMO | $196B | 29.2 | 19.3 | 4.3 | 20.9 | 3.8 | 40.9% | 6.2% | 11.3% | 2.82% |
Auto-seeded from sector. Click any ticker to switch.
Ownership
Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.
Top institutional holders
Top-10 concentration: 46.2%
| Holder | Shares | % out |
|---|---|---|
| Blackrock Inc. | 12,151,276 | 11.32% |
| Ingalls & Snyder LLC | 7,608,716 | 7.09% |
| Renaissance Technologies, LLC | 5,682,783 | 5.29% |
| Vanguard Portfolio Management LLC | 4,820,568 | 4.49% |
| Vanguard Capital Management LLC | 4,077,196 | 3.80% |
| Parallel Advisors, LLC | 3,977,404 | 3.71% |
| State Street Corporation | 3,200,946 | 2.98% |
| FMR, LLC | 3,190,192 | 2.97% |
| Geode Capital Management, LLC | 2,713,519 | 2.53% |
| First Trust Advisors LP | 2,173,376 | 2.02% |
Insider activity · 90d
0 buys / 10 sells · ratio 0.0 · Finnhub
- Guyer William M 130,000
- Guyer William SELL 3,985 @ $93.54
- Guyer William SELL 4,937 @ $93.11
- Guyer William M 23,985 @ $21.65
- Maduck Sean M 116,986
- Maduck Sean SELL 9,755 @ $89.31
- Maduck Sean SELL 20,930 @ $88.51
- Maduck Sean SELL 23,731 @ $87.33
- Maduck Sean M 34,755 @ $8.27
- MAHONEY DAVID L SELL 26,147 @ $84.53
Analyst estimates
FinnhubWhat Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.
SEC filings
The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.
| Form | Filed | Description | Action |
|---|---|---|---|
| 4 | 2026-07-17 | 4 | view · |
| 4 | 2026-07-17 | 4 | view · |
| 4 | 2026-07-08 | 4 | view · |
| 4 | 2026-07-08 | 4 | view · |
| 4 | 2026-07-06 | 4 | view · |
| 4 | 2026-06-18 | 4 | view · |
| 4 | 2026-06-18 | 4 | view · |
| 8-K | 2026-06-17 | 8-K | view · |
| 4 | 2026-06-17 | 4 | view · |
| 4 | 2026-06-04 | 4 | view · |
| 4 | 2026-06-03 | 4 | view · |
| 4 | 2026-06-03 | 4 | view · |
| 4 | 2026-06-03 | 4 | view · |
| 4 | 2026-06-03 | 4 | view · |
| 4 | 2026-06-03 | 4 | view · |
| 8-K | 2026-06-03 | 8-K | view · |
| 4 | 2026-06-02 | 4 | view · |
| 4 | 2026-05-29 | 4 | view · |
| 4 | 2026-05-29 | 4 | view · |
| 4 | 2026-05-29 | 4 | view · |
| 8-K | 2026-05-28 | 8-K | view · |
| 4 | 2026-05-26 | Insider transaction (Form 4) | view · |
| 4 | 2026-05-26 | 4 | view · |
| 4 | 2026-05-26 | 4 | view · |
| 4 | 2026-05-26 | 4 | view · |
| 4 | 2026-05-26 | 4 | view · |
| 4 | 2026-05-26 | 4 | view · |
| 4 | 2026-05-26 | 4 | view · |
| 4 | 2026-05-15 | 4 | view · |
| 4 | 2026-05-07 | 4 | view · |
| 4 | 2026-05-05 | 4 | view · |
| 10-Q | 2026-04-30 | 10-Q | view · |
| 8-K | 2026-04-30 | 8-K | view · |
| 4 | 2026-04-24 | 4 | view · |
| DEF 14A | 2026-04-17 | DEF 14A | view · |
| 4 | 2026-04-08 | 4 | view · |
| 4 | 2026-04-08 | 4 | view · |
| 4 | 2026-03-27 | 4 | view · |
| 8-K | 2026-03-25 | 8-K | view · |
| 4 | 2026-03-24 | 4 | view · |
| 4 | 2026-03-24 | 4 | view · |
| 4 | 2026-03-19 | Insider transaction (Form 4) | view · |
| 4 | 2026-03-17 | 4 | view · |
| 4 | 2026-03-17 | 4 | view · |
| 4 | 2026-03-06 | 4 | view · |
| 4 | 2026-03-04 | 4 | view · |
| 4 | 2026-03-04 | 4 | view · |
| 4 | 2026-03-04 | 4 | view · |
| 4 | 2026-03-04 | 4 | view · |
| 4 | 2026-03-04 | 4 | view · |
| 4 | 2026-03-03 | 4 | view · |
| 4 | 2026-03-03 | 4 | view · |
| 4 | 2026-03-03 | 4 | view · |
| 4 | 2026-03-03 | 4 | view · |
| 4 | 2026-03-03 | 4 | view · |
| 4 | 2026-03-03 | 4 | view · |
| 4 | 2026-03-03 | 4 | view · |
| 4 | 2026-02-26 | 4 | view · |
| 10-K | 2026-02-24 | 10-K | view · |
| 8-K | 2026-02-24 | 8-K | view · |
About CORT
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.
Options picks · CORT
ITM + OTM ideas from the latest scanLoading…
Congress trades · CORT
STOCK Act disclosuresLoading…
SEC filings & insiders · CORT
EDGAR · liveLoading…
Holders · CORT
Institutions & insider activityLoading…